Approval of Modification of draft Scheme of Amalgamation submitted on November 12, 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors of Venmax Drugs and Pharmaceuticals Ltd (BSE: 531015) approved an amendment to Para 2.2 (Share Capital Clause) of the draft Scheme of Amalgamation originally submitted on November 12, 2025, with Hatri Pharma Private Limited as the Transferor Company. The amendment updates Venmax's paid-up equity share capital from 80,07,930 shares (Rs. 8.01 crore) to 1,15,82,930 shares (Rs. 11.58 crore), reflecting the conversion of 35,75,000 warrants. Pending convertible warrants have correspondingly reduced from 72,56,400 to 36,81,000. Hatri Pharma is engaged in manufacturing of drug intermediates, fine chemicals, and contract manufacturing, while Venmax is in trading of nutraceuticals and drug intermediates. The merger, to be filed with NCLT Hyderabad with an Appointed Date of April 1, 2025, aims to create a vertically integrated pharma business with cost efficiencies and scale benefits.
This is a routine capital clause update to the existing amalgamation scheme, reflecting recent warrant conversions. The merger will consolidate manufacturing capabilities (Hatri) and trading operations (Venmax) under one listed entity, potentially improving margins. No immediate share price trigger, but shareholders should track NCLT approval timelines and the final share swap ratio announcement.